Home > Research > Publications & Outputs > Neuroprotective effects of an oxyntomodulin ana...

Links

Text available via DOI:

View graph of relations

Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. / Liu, WeiZhen; Li, Yanwei; Jalewa, Jaishree; Saunders-Wood, Taylor; Li, Lin; Hölscher, Christian.

In: European Journal of Pharmacology, Vol. 765, 2015, p. 284-290.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Liu, W, Li, Y, Jalewa, J, Saunders-Wood, T, Li, L & Hölscher, C 2015, 'Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease', European Journal of Pharmacology, vol. 765, pp. 284-290. https://doi.org/10.1016/j.ejphar.2015.08.038

APA

Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L., & Hölscher, C. (2015). Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. European Journal of Pharmacology, 765, 284-290. https://doi.org/10.1016/j.ejphar.2015.08.038

Vancouver

Author

Liu, WeiZhen ; Li, Yanwei ; Jalewa, Jaishree ; Saunders-Wood, Taylor ; Li, Lin ; Hölscher, Christian. / Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. In: European Journal of Pharmacology. 2015 ; Vol. 765. pp. 284-290.

Bibtex

@article{7e18889e9f174ed18aa670a4c784d850,
title = "Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease",
abstract = "Oxyntomodulin is a hormone and a growth factor. It activates two receptors, the Glucagon-like peptide 1 (GLP-1) and the glucagon receptor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first positive results. d-Ser2-oxyntomodulin (Oxy) is a protease resistant oxyntomodulin analogue that has been developed to treat diabetes. Here we demonstrate for the first time that such analogues have neuroprotective effects. The drug showed protective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected daily (20mg/kg i.p.) for 7 days, and Oxy injected once-daily for 14 days i.p. Oxy treatment prevented or reversed the MPTP- induced motor impairment (Rotarod, spontaneous locomotion, swim activity, muscle strength test), the MPTP-induced reduction in Tyrosine Hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia, the reduction of the synaptic marker synapstophysin, the inactivation of the growth factor kinase Akt/PKB and of the anti-apoptotic signaling molecule Bcl-2, and the increase of levels of the pro-inflammatory cytokine TNF-α. The results demonstrate that oxyntomodulin analogues show promise as a novel treatment of PD.",
keywords = "Growth factor, Incretin, GLP-1, Glucagon, Insulin, Neurodegeneration, Mice",
author = "WeiZhen Liu and Yanwei Li and Jaishree Jalewa and Taylor Saunders-Wood and Lin Li and Christian H{\"o}lscher",
year = "2015",
doi = "10.1016/j.ejphar.2015.08.038",
language = "English",
volume = "765",
pages = "284--290",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease

AU - Liu, WeiZhen

AU - Li, Yanwei

AU - Jalewa, Jaishree

AU - Saunders-Wood, Taylor

AU - Li, Lin

AU - Hölscher, Christian

PY - 2015

Y1 - 2015

N2 - Oxyntomodulin is a hormone and a growth factor. It activates two receptors, the Glucagon-like peptide 1 (GLP-1) and the glucagon receptor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first positive results. d-Ser2-oxyntomodulin (Oxy) is a protease resistant oxyntomodulin analogue that has been developed to treat diabetes. Here we demonstrate for the first time that such analogues have neuroprotective effects. The drug showed protective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected daily (20mg/kg i.p.) for 7 days, and Oxy injected once-daily for 14 days i.p. Oxy treatment prevented or reversed the MPTP- induced motor impairment (Rotarod, spontaneous locomotion, swim activity, muscle strength test), the MPTP-induced reduction in Tyrosine Hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia, the reduction of the synaptic marker synapstophysin, the inactivation of the growth factor kinase Akt/PKB and of the anti-apoptotic signaling molecule Bcl-2, and the increase of levels of the pro-inflammatory cytokine TNF-α. The results demonstrate that oxyntomodulin analogues show promise as a novel treatment of PD.

AB - Oxyntomodulin is a hormone and a growth factor. It activates two receptors, the Glucagon-like peptide 1 (GLP-1) and the glucagon receptor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first positive results. d-Ser2-oxyntomodulin (Oxy) is a protease resistant oxyntomodulin analogue that has been developed to treat diabetes. Here we demonstrate for the first time that such analogues have neuroprotective effects. The drug showed protective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected daily (20mg/kg i.p.) for 7 days, and Oxy injected once-daily for 14 days i.p. Oxy treatment prevented or reversed the MPTP- induced motor impairment (Rotarod, spontaneous locomotion, swim activity, muscle strength test), the MPTP-induced reduction in Tyrosine Hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia, the reduction of the synaptic marker synapstophysin, the inactivation of the growth factor kinase Akt/PKB and of the anti-apoptotic signaling molecule Bcl-2, and the increase of levels of the pro-inflammatory cytokine TNF-α. The results demonstrate that oxyntomodulin analogues show promise as a novel treatment of PD.

KW - Growth factor

KW - Incretin

KW - GLP-1

KW - Glucagon

KW - Insulin

KW - Neurodegeneration

KW - Mice

U2 - 10.1016/j.ejphar.2015.08.038

DO - 10.1016/j.ejphar.2015.08.038

M3 - Journal article

C2 - 26302060

VL - 765

SP - 284

EP - 290

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -